Treatment of impetigo caused by Staphylococcus aureus or Streptococcus pyogenes in adults and children aged 2 months or older.
Topical quinolone antimicrobial. Inhibits bacterial DNA replication enzymes, DNA gyrase A, and topoisomerase IV.
Apply a thin layer topically to affected area q12hr for 5 days; not to exceed 100 cm2 area in adults and adolescents or to exceed 2% of body surface area for children aged 2 months to 12 years.
Approval was based on two phase 3 multicenter, randomized, double-blind, placebo-controlled studies (n=723). Both phase 3 pivotal studies demonstrated ozenoxacin cream 1% applied topical twice daily for 5 days was superior to placebo on both the clinical and the bacteriological endpoints.
Medscape © 2018 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L Windle. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review - Medscape - Jan 11, 2018.